The market capacity of blood products will show rapid growth

With the improvement of medical level and the improvement of medical security system in China, the clinical use of blood products is increasing, with the help of the new version of the medical insurance catalog of blood products product adaptation and other factors, the future market capacity will continue to show rapid growth.
2016, China issued 3,949 batches of vaccines, or about 646 million copies, 4,025 batches of blood products, amounting to about 5,927.8 million bottles, and 836 batches of blood screening reagents, or about 878 million copies, according to the annual report on the issuance of biological products. Annual data provide information on domestic vaccine and blood products market demand and availability.
2016, the top three products in the domestic sample hospital blood products market were human haemoglobin, human immunoglobulin, recombinant human coagulation factor VIII. It is worth noting that: human haemoglobin sales reached 2.31 billion yuan, sample hospital drugs ranked 1st, human immunoglobulin sales of 1.04 billion yuan, sample hospital drugs ranked 22nd, which is the domestic blood products market more than 2 billion yuan and 1 billion yuan two heavy products.
added to the 2017 edition of the health insurance catalog, the industry will continue to have high growth in the future. The following use of domestic sample hospital data, focusing on the analysis of human haemoglobin, human immunoglobulin, recombinant human coagulation factor VIII. three blood products market situation.blood products are growing rapidly
2016 sales: 4.30 billion yuan, up 21.6% YoY
Blood products are made from human blood separation and extracted products for use in patients with different conditions. The main categories of blood products are: human haemoglobin, immunoglobulin and clotting factors, of which coagulation factor products are the most. From the development of the domestic blood products industry, the domestic blood products market is greatly affected by the policy, mainly led by the government, with the expansion of demand, the domestic blood products market is still very tight.
According to domestic sample hospital statistics, sales of blood products in sample hospitals in 2005 were 750 million yuan, and sales of blood products in sample hospitals reached 4.30 billion yuan in 2016, an increase of 21.6% over the same period a year earlier, and the overall market grew 5.8 times; Blood products experienced significant lows in 2005-2008, but have maintained high growth for eight consecutive years since 2009.
2016, there were 14 blood products entering the sample hospital, and the top 10 products were human haemoglobin (sales of 2.31 billion yuan, the same between), human immunoglobulin (1.04 billion yuan), recombinant human clotting factor VIII. (270 million yuan), human fibrinogen (170 million yuan), human coagulation factor VIII. (100 million yuan), hepatitis B immunoglobulin (97.02 million yuan), human fibrin adhesive (95.11 million yuan), recombinant human coagulation factor VII.a (53.97 million yuan), tematostogen immunoglobulin (523.6 billion yuan), clotting enzyme complex 4825 (billion yuan). Among them, human haemoglobin accounted for 53.8%, human immunoglobulin accounted for 24.3%, recombinant human coagulation factor VIII. 6.3%, the top three products accounted for 84.3% of the overall market share, human haemoglobin still occupies half of the domestic market for blood products.
of the top 10 products in the world are: human haemoglobin (up 14.6% YoY, the same between), human immunoglobulin (19.7%), recombinant human coagulation factor VIII.(57.5%), human fibrinogen (140.5%) 7%), human immunoglobulin B (28.5%), human fibrin adhesive (27.8%), recombinant human coagulation factor VII.a (12.0%), teatum man immunoglobulin (25.9%). In addition, rabies patient immunoglobulin sales ranked 11th, but increased by 98.8% year-on-year, the performance is also very prominent. From this, it can be seen that blood products in the entire pharmaceutical industry growth rate of less than 10%, many products growth rate remains high, reflecting the rigid demand for blood products market and rapid growth.
2016, there were nearly 30 production enterprises involved in blood products in sample hospitals, of which the top 10 were: Baxter (Baxter, with sales of 660 million yuan, the same between), Grifols (510 million yuan), Sanofi (Sanofi, 460 million yuan), Taibang, Shandong (340 million yuan), ZLBBehring AG (310 million yuan), Sichuan Yuanyang Pharmaceuticals (270 million yuan), Shanghai Laishi (240 million yuan), Henan Xinxiang Huayuan Bio (220 million yuan), Bayer (Bayer, 180 million yuan), Guizhou Taibang (170 million yuan), the top 10 enterprises accounted for 77.9% of the share. In the top 10 enterprises, there are five local enterprises and five foreign enterprises. Among them, the share of foreign enterprises accounted for 62.9%, local enterprises accounted for 37.1%. After years of development of the blood products market, the advantages of foreign enterprises gradually narrowed, the concentration of the local enterprise market increased year by year.people haemoglobin list is difficult
2016 sales: 2.31 billion yuan, an increase of 14.6% year-on-year
people haemoglobin, also known as serum albumin, is the most commonly used blood products in the clinic. The product can be used as both a therapeutic drug to replenish plasma capacity and as an auxiliary to the prescription of injectable drugs. Because of its wide clinical application, it is one of the few blood products allowed to be imported by the state. In recent years, human haemoglobin has been the domestic drug market's most sought-after varieties. In 2011-2014, the product ranked in the top three domestic sample hospital drug use, and in 2015-2016 for the second consecutive year ranked first.
According to domestic sample hospital statistics, the sales of human haemoglobin in sample hospitals in 2005 were 490 million yuan, and sales in 2016 reached 2.13 billion yuan, an increase of 14.6% over the same period a year earlier, and the overall market grew 4.7 times; Since the listing of human haemoglobin, the domestic long-term in short supply, mainly import-oriented, with the domestic began to restrict the import of human haemoglobin, local blood products enterprises gradually strengthened. Since 2009, the domestic human albumin market has been on an upward trend. In 2017, the new version of the health insurance catalog also added human haemoglobin adaptation, the scope of payment is limited to rescue, severe or due to cirrhosis of the liver, cancer caused by chest and abdominal water and albumin less than 30g/L patients, restrictions have been liberalized, for the domestic academic promotion ability of enterprises to add momentum.
2016, there were 25 production enterprises involved in human haemoglobin in sample hospitals, of which the top five were: Baxter (Baxter, with sales of 600 million yuan, the same between), Grifols (5.1) Billion yuan), Sanofi (Sanofi, 460 million yuan), ZLBBehringAG (310 million yuan), Shandong Taibang biological products (95.54 million yuan), the top five enterprises accounted for 84.8 percent of the share. Overall, the import enterprises occupy an absolute advantage, the proportion of domestic varieties significantly increased. Domestic enterprises such as Shandong Taibang biological products, Guizhou Taibang Biologicals, Chengdu Shengsheng Pharmaceuticals, Sichuan Yuanda Puyang and so on in the human haemoglobin market has a place.human immunoglobulin trend
2016 sales: 1.04 billion yuan, up 19.7% YoY
immunoglobulin is mainly divided into human immunoglobulin, specific human immunoglobulin. In 2016, the human immunoglobulin market exceeded 1 billion yuan, ranking 22nd in sample hospital medication. Among specific human immunoglobulins, sales of immunoglobulin in hepatitis B were 97.02 million yuan, up 28.5% YoY; The market of these three specific human immunoglobulin products is relatively small, but the growth rate is more prominent.
According to domestic sample hospital statistics, the sales of human immunoglobulin in sample hospitals in 2005 were 140 million yuan, and sales in 2016 reached 1.04 billion yuan, an increase of 19.7% over the same period a year earlier, and the overall market grew 7.5 times; The 2017 edition of the health insurance catalog adjusted the scope of application of human immunoglobulin, in which the static injection of human immunoglobulin is limited primary immunoglobulin deficiency; neonatal sepsis; heavy primary immunoplate platelet reduction; Kawasaki disease; systemic severe muscle weakness; and 6 adaptations of acute Greenbali syndrome. The new addition of autologism to the static injection of human immunoglobulin provides an opportunity for academic promotion and sales in the future.
2016, there were 23 production enterprises involved in human immunoglobulin in sample hospitals, of which the top 5 enterprises were: Shandong Taibang Biological Products (with sales of 180 million yuan, the same between 2nd), Sichuan Yuanda Puyang Pharmaceuticals (1.5) 600 million yuan), Henan Xinxiang Huayuan Bio (120 million yuan), Guizhou Taibang Biological Products (104 million yuan), Tonglu Biopharmaceutical (85.47 million yuan), the top five enterprises accounted for 62.4% of the share. Among the above-mentioned enterprises, the rapid growth of Henan Xinxiang Hualu bio, Guizhou Taibang biological products, the same way biopharmaceuticals, the growth rate of 3 enterprises are more than 50.0%, the market performance is not bad. At present, there are no domestic imports of human immunoglobulin manufacturers, market competition is more moderate.recombinant human coagulation factor VIII. has shown strength
2016 sales: 270 million yuan, up 57.5% YoY
II., human fibrinogen, human coagulation factor VIII., human fibrin adhesive, recombinant human coagulation factor VII.a, coagulation enzyme compound, human fibrin gel, histamine human immunoglobulin, recombinant human gel factor IX. Among these products in 2016, the top 5 are: recombinant human coagulation factor VIII. (sales of 270 million yuan, the same between), human fibrinogen (170 million yuan), human coagulation factor VIII.(1.2) 0 billion yuan), human fibrin adhesive (95.11 million yuan), recombinant human coagulation factor VII.a (53.97 million yuan), the top 5 products in addition to human coagulation factor VIII. Sales decreased, the other four products growth is more obvious.
According to domestic sample hospital statistics, in 2008 sample hospital recombinant human coagulation factor VIII. Sales of 3.05 million yuan, sales in 2016 reached 270 million yuan, an increase of 57.5% over the same period a year earlier, the overall market growth of nearly 50 times; In fact, the market for recombinant human coagulation factor VIII has been relatively moderate from 2009 to 2015, and the market grew rapidly in 2016, leaping into the top three blood products. The new medical insurance catalogue for 2017 adjusts the scope of application of recombinant human coagulation factor VIII. Recombinant human coagulation factor VIII. As a special effects product of hemophilia alternative treatment, its tight supply has aroused widespread concern.
2016, there were three production enterprises involved in the reorganization of human coagulation factor VIII in sample hospitals, all of which were foreign enterprises. Among them, Bayer's "Bayer" sales were 180 million yuan, Baxter's "Bains" sales were 64.01 million yuan, Wyeth's "Renjie" sales were 30.52 million yuan, and the market share was 65.1%, 23.7% and 11.3%, respectively. Bayer's "Baykoc" market has been at the top of the list and accounts for more than 60% of the market.
Bayer injection recombinant human coagulation factor VIII. "Baikoc" was approved to enter the Chinese market in 2007, the drug is the first listed gene recombinant human coagulation factor VIII.A conclusion<<<
blood products are a special drug with significant clinical use value in China, the current per capita use of blood products in China is still far below the international level, with the improvement of China's medical level and the improvement of the medical security system, the clinical use of blood products is increasing, with the help of the new version of the medical insurance catalog of blood products product adaptation and other factors, the future market capacity will continue to show rapid growth. (Medical Economics)